Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India

Abstract

Background Globally, 16 billion injections are administered each year of which 95% are for curative care. India contributes 25-30% of the global injection load. Over 63% of these injections are reportedly unsafe or deemed unnecessary. Objectives To assess the incremental cost per quality-adjusted life-year (QALY) gained with the introduction of safetyengineered syringes (SES) as compared to disposable syringes for therapeutic care in India. Methods A decision tree was used to compute the volume of needle-stick injuries (NSIs) and reuse episodes among healthcare professionals and the patient population. Subsequently, three separate Markov models were used to compute lifetime costs and QALYs for individuals infected with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Three SES were evaluated-reuse prevention syringe (RUP), sharp injury prevention (SIP) syringe, and syringes with features of both RUP and SIP. A lifetime study horizon starting from a base year of 2017 was considered appropriate to cover all costs and consequences comprehensively. A systematic review was undertaken to assess the SES effects in terms of reduction in NSIs and reuse episodes. These were then modelled in terms of reduction in transmission of blood-borne infections, life-years and QALYs gained. Future costs and consequences were discounted at the rate of 3%. Incremental cost per QALY gained was computed to assess the cost-effectiveness. A probabilistic sensitivity analysis was undertaken to account for parameter uncertainties. Results The introduction of RUP, SIP and RUP + SIP syringes in India is estimated to incur an incremental cost of Indian

Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India

“…The use of per capita GDP as cost-effectiveness threshold is recommended by Indian Government’s Health Technology Assessment (HTAIn) agency and used by many recent HTA studies conducted in Indian context. 15 - 18 All future costs and consequences were discounted at 3%. 19…”

Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India

“…In view of the absence of EQ-5D-5L tariff values from India, the draft guidelines by health technology assessment board of India (HTAIn) recommends the use of Thailand-specific tariff values until the Indian value-set is generated (11). Moreover, recent economic evaluations that were commissioned by HTAIn have also used tariff values of Thailand for generating QoL utility scores (30–32).…”

Economic evaluation of implementing a decentralised Hepatitis B virus diagnostic intervention under National Viral Hepatitis Control Programme in Tamil Nadu, South India

“…For prevalence of HBV, we conducted systematic review from published prevalence studies done in Tamil Nadu and was used to populate the model (Table 3). Quality of life (QoL) for each health state was obtained from previously published studies on cost‐effectiveness of HBV interventions [28]. Life expectancy values were taken from the life table published for Indian population based on Sample Registration System data [29].…”